Trial · NCT07911930
LacriFill Canalicular Occlusion for Dry Eye After LASIK
NCT07911930, Not applicable, Not yet recruiting, Mann Eye Institute
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. LacriFill Canalicular Occlusion for Dry Eye After LASIK. Trials, record NCT07911930. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911930
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LacriFill Canalicular Occlusion for Dry Eye After LASIK
- NCT number
- NCT07911930
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 75 participants, estimated
- Lead sponsor
- Mann Eye Institute
- Conditions
- Dry Eye Syndrome
- Interventions
- LacriFill Canalicular Filler
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in Ocular Surface Disease Index (OSDI) score | 12 weeks | The OSDI© is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. The OSDI© is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function. |
| Secondary | Change from baseline in Ocular Surface Disease Index (OSDI) score | 12 weeks | The OSDI© is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal subjects and patients with dry eye disease. The OSDI© is a valid and reliable instrument for measuring dry eye disease (normal, mild to moderate, and severe) and effect on vision-related function. |
| Secondary | Proportion of subjects achieving ≥10-point improvement in OSDI score | 12 weeks | Proportion of subjects achieving an improvement of 10 points or more in OSDI score from baseline following bilateral LASIK. |
| Secondary | Proportion of subjects achieving OSDI score <13 | 12 weeks | Proportion of subjects with an OSDI score below 13 (normal range) at the 12-week postoperative visit. |
| Secondary | Change from baseline in tear break-up time (TBUT) | 12 weeks | |
| Secondary | Change from baseline in corneal fluorescein staining (National Eye Institute Corneal Staining Scale) | 12 weeks | |
| Secondary | Uncorrected distance visual acuity (UDVA) | 12 weeks | |
| Secondary | Corrected distance visual acuity (CDVA) | 12 weeks | |
| Secondary | Manifest refraction | 12 weeks | |
| Secondary | Artificial tear usage and time to discontinuation of routine artificial tears | 12 weeks | Artificial tear usage, time to discontinuation of routine artificial tears, and requirement for rescue dry eye therapy through the 12-week postoperative visit. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911930
GET https://conductscience.org/api/trials/v1/NCT07911930/registered